Atractylenolide III inhibits epithelialmesenchymal transition in small intestine epithelial cells by activating the AMPK signaling pathway.
Mol Med Rep
; 25(3)2022 Mar.
Article
en En
| MEDLINE
| ID: mdl-35088892
ABSTRACT
Compared with the available drugs for the treatment of fibrosis in other organs, the development of intestinal antifibrosis drugs is limited. Therefore, it is of practical significance to examine novel drugs to delay or block the development of intestinal fibrosis. The present study aimed to investigate the effect of atractylenolide III (ATLIII) on intestinal fibrosis. An MTT assay was used to detect the effect of ATLIII on the activity of IEC6 cells. The migration and invasion of fibrotic cells stimulated with TGFß were determined via wound healing and Transwell assays. An immunofluorescence assay and western blotting were conducted to assess the expression levels of protein associated with epithelialmesenchymal transition (EMT). The role of the AMPactivated protein kinase (AMPK) pathway was verified using compound C (an AMPK inhibitor) treatment. The results of the present study indicated that ATLIII had no effect on the cells at a dose of 120 µmol/l. Moreover, ATLIII can inhibit the invasion and migration of cells induced by TGFß1, as well as block the EMT process. It was found that ATLIII could also activate the AMPK pathway. Furthermore, compound C reduced the inhibitory effect of ATLIII on stimulated cells, which indicated that the AMPK pathway plays a role in the inhibition process. In conclusion, ATLIII may inhibit the EMT of IEC6 cells stimulated with TGFß1 by activating the AMPK signaling pathway.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Proteínas Quinasas Activadas por AMP
/
Transición Epitelial-Mesenquimal
Límite:
Animals
Idioma:
En
Revista:
Mol Med Rep
Año:
2022
Tipo del documento:
Article